HuGE Literature Finder
Records
1
-
17
| Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). International journal of cancer 2021 Feb 148 (3): 682-691. Assenat Eric, Mineur Laurent, Mollevi Caroline, Lopez-Crapez Evelyne, Lombard-Bohas Catherine, Samalin Emmanuelle, Portales Fabienne, Walter Thomas, de Forges Hélène, Dupuy Marie, Boissière-Michot Florence, Ho-Pun-Cheung Alexandre, Ychou Marc, Mazard Thiba |
| A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational new drugs 2019 Nov . Bendell Johanna C, Bischoff Helge G, Hwang Jimmy, Reinhardt Hans Christian, Zander Thomas, Wang Xuejing, Hynes Scott, Pitou Celine, Campbell Robert, Iversen Philip, Farrington Daphne L, Bell-McGuinn Katherine, Thomas Micha |
| Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
| Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. Cancer research and treatment : official journal of Korean Cancer Association 2018 Jan . Yoo Changhoon, Han Boram, Kim Hyeong Su, Kim Kyu-Pyo, Kim Deokhoon, Jeong Jae Ho, Lee Jae-Lyun, Kim Tae Won, Kim Jung Han, Choi Dae Ro, Ha Hong Il, Seo Jinwon, Chang Heung-Moon, Ryoo Baek-Yeol, Zang Dae You |
| Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. Cancer management and research 2018 10 2915-2924. Chen Duke, Wu Yu-Shen, Lin Huapeng, Wang Yihan, Li Longhao, Zhang T |
| A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. Seminars in oncology 2017 Feb 44 (1): 24-33. Boisdron-Celle Michèle, Metges Jean Philippe, Capitain Olivier, Adenis Antoine, Raoul Jean Luc, Lecomte Thierry, Lam You Heng, Faroux Roger, Masliah Claude, Poirier Anne Lise, Berger Virginie, Morel Alain, Gamelin Eri |
| Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. British journal of cancer 2016 Feb 114 (4): 372-80. Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero |
| A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 943-9. Chen J S, Hsu C, Chiang N J, Tsai C S, Tsou H H, Huang S F, Bai L Y, Chang I C, Shiah H S, Ho C L, Yen C J, Lee K D, Chiu C F, Rau K M, Yu M S, Yang Y, Hsieh R K, Chang J Y, Shan Y S, Chao Y, Chen L T, |
| Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. Surgery today 2014 Aug 44 (8): 1457-64. Saeki Hiroshi, Emi Yasunori, Kumashiro Ryuichi, Otsu Hajime, Kawano Hiroyuki, Ando Koji, Ida Satoshi, Kimura Yasue, Tokunaga Eriko, Oki Eiji, Morita Masaru, Shimokawa Mototsugu, Maehara Yoshihi |
| Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer research 2014 Apr 34 (4): 1967-73. Iwamoto Shigeyoshi, Hazama Shoichi, Kato Takeshi, Miyake Yasuhiro, Fukunaga Mutsumi, Matsuda Chu, Bando Hiroyuki, Sakamoto Junichi, Oba Koji, Mishima Hideyu |
| Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. European journal of cancer (Oxford, England : 1990) 2013 Sep 49 (13): 13. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L |
| FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Aug 24 (8): 2062-7. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone |
| Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013 Aug 119 (15): 2754-64. Karampeazis Athanasios, Voutsina Alexandra, Souglakos John, Kentepozidis Nikos, Giassas Stelios, Christofillakis Charalambos, Kotsakis Athanasios, Papakotoulas Pavlos, Rapti Ageliki, Agelidou Maria, Agelaki Sofia, Vamvakas Lambros, Samonis George, Mavroudis Dimitris, Georgoulias Vassil |
| Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Feb 24 (2): 412-9. André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A, |
| Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 2012 Dec 118 (24): 6144-51. Kurzrock Razelle, Goel Sanjay, Wheler Jennifer, Hong David, Fu Siqing, Rezai Keyvan, Morgan-Linnell Sonia K, Urien Saik, Mani Sridhar, Chaudhary Imran, Ghalib Mohammed H, Buchbinder Aby, Lokiec François, Mulcahy Ma |
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The lancet oncology 2012 Nov . Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L |
| Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. International journal of colorectal disease 2011 Aug 26 (8): 1025-33. Zhang Linlin, Ma Li, Zhou Qingh |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 20, 2022
- Content source: